Navigation Links
Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine
Date:6/11/2008

stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI, discovered by researchers at the Walter Reed Army Institute of Research, taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent travelers' diarrhea. For more information on Iomai, please visit http://www.iomai.com.

Iomai announced on May 12 that it has entered into an agreement with Intercell AG in which Intercell will acquire Iomai for $6.60 a share.

Some matters discussed in this press release constitute "forward-looking statements" that involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. Such forward-looking statements include statements about the patch vaccine being a prophylaxis for travelers' diarrhea, the timing for commencing Phase III studies, and bringing the product candidate to market; the potential size of the market for a travelers' diarrhea vaccine; the applicability of TCI technology to other pathogens; that, if approved, Iomai's vaccine would be the first available in the U.S.; and about the anticipated acquisition of Iomai by Intercell. Applicable risks and uncertainties include, among others, that Iomai may not be able to enroll sufficient numbers of patients in future clinical trials; that future clinical trials may not replicate results seen in the trial described in this press release; that Iomai may be unable to obtain the regulatory approval
'/>"/>

SOURCE Iomai Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
3. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
4. Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5
5. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
6. Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch
7. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Calif. , May 21, 2013   ... announced today the publication of study results involving ... CyberKnife® Robotic Radiosurgery System, the most widely used ... The study followed 304 patients for a median ... post-treatment and found that 97 percent of patients ...
(Date:5/21/2013)... 21, 2013  Healthcare organizations expanding into emerging markets ... , India and ... no shortcuts.  This is proving particularly challenging, considering the ... must change the dialogue around BRIC, as it is ... and building regional partnerships to build a sustainable business. ...
(Date:5/21/2013)... 2013  BioRestorative Therapies, Inc. ("BRT" or the "Company") ... developing stem cell based therapies for various personal applications, ... President and CEO, will be presenting at the Marcum ... held on Thursday, May 30, 2013 at the Grand ... New York City.  Mr. Weinreb,s presentation will take place ...
Breaking Medicine Technology:New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 2New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 3Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 2Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 3Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 4BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3
... track to report primary study results in third quarter ... (Nasdaq: NVAX ) announced today that enrollment ... trial of its trivalent virus-like particle (VLP) seasonal influenza ... evaluating a VLP vaccine against the H3N2, H1N1, and ...
... - Data on BIBW 2992, an Irreversible, Dual EGFR ... Treatment of NSCLC Patients with EGFR Activating Mutations - ... Ovarian Cancer-RIDGEFIELD, Conn., May 14 Boehringer Ingelheim will ... compounds, BIBW 2992 and BIBF 1120 at the 2009 ...
Cached Medicine Technology:Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial 2Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial 3Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 2Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 3Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 4Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 5Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 6Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 7Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 8Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 9Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 10
(Date:5/21/2013)... GA (PRWEB) May 21, 2013 Patients of ... Care who have lost teeth due to gum disease and ... surgery for gum disease treatment with laser gum surgery. ... which have the highest success rate out of all tooth ... (LANAP) is a relatively new procedure cleared by the Food ...
(Date:5/21/2013)... Kan. Primary care practice transformation on a ... care reform efforts aimed at achieving better outcomes, ... emerging evidence that transformation toward the patient-centered medical ... health care environment, the U.S. Department of Health ... Quality funded 14 studies to learn more about ...
(Date:5/21/2013)... May 21, 2013 Parker Waichman LLP, ... of victims injured by defective medical devices, is addressing ... Joint Surgery on May 15, 2013. The study found ... identify complications that occur in patients with metal-on-metal hip ... ( http://www.jbjs.org/article.aspx?articleid=1684770 ) , “We’ve known ...
(Date:5/21/2013)... 21, 2013 Artisan Business Group ... Summit: Dealmakers Conference in Long Beach, California on ... on exploring alternative finance through EB-5 immigrant investors ... legal and economic information, and updates to project ... within the EB-5 industry. , "Our goal ...
(Date:5/21/2013)... 2013 Arizona State University is ... to develop their ideas into solutions, products and ... The university is recruiting participants for AREA48 (Applied ... that provides early-stage entrepreneurs with opportunities to access ... to anyone, ASU is particularly seeking participation from ...
Breaking Medicine News(10 mins):Health News:Shenk Dental Care Stimulates Bone Growth for Gum Disease Patients Seeking Dental Implants with Laser Gum Surgery in Atlanta, GA 2Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 2Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 3Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 4Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 5Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 6Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Artisan Business Group to Host EB-5 Investment Conference in Long Beach, California 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4
... the ban on mercury based flu vaccines given to pregnant ... six weeks . This decision was made due to a ... free children's vaccine is manufactured by Sanofi pasteur, and the ... speed up production to meet the state's need. ,The ...
... new artificial pump along with the intake of certain drugs ... say scientists in Britain.// ,The temporary pumps, known ... patients with severe heart failure while they await transplantation, reported ... on the work of one of the heart's four chambers, ...
... biggest killer disease in the UK during the 1800s has made ... to 2005. //Th number of cases have been rising from the ... , causing great concern to government health agencies. ,The ... Louis Stevenson , was thought to have been conquered by very ...
... unhappy lot because nearly 50 percent of the clan is ... in their careers.// A new study has claimed that nearly ... of chemicals, soaps and shampoos that render constantly moist hands., ... careers, unable to carry on with their jobs when the ...
... abused in early stages of life may grow up to ... University of Chicago. //This study was conducted on baby rhesus ... may lead to the production of less seratonin, a chemical ... causes anxiety and depression.It may also lead to impulsive aggression ...
... down with acute symptoms of dengue, later confirmed positive for ... alarming figure of 741. ,Nearly 31 deaths have ... Peshawar. The National Institute of Health (NIH) has reiterated via ... the disease are pouring in from all over Pakistan which ...
Cached Medicine News:Health News:New Device May Help Heal A Failing Heart 2Health News:TB Returns , Sharp Rise In Cases In UK 2Health News:Hair-raising issues of hairdressers 2Health News:An abused child may grow up to be an abusive parent 2Health News:An abused child may grow up to be an abusive parent 3
Valleylab Surgistat II generator provides exceptional performance, reliability, and safety benefits in a compact, easy to use unit....
Sabre 180, 230V, 50Hz is a powerful niche generator....
Microcontroller-based isolated electrosurgical generator, designed for all general purpose surgical procedures. Unit includes: Instant Response technology, adaptive REM system, isolated output, CEM c...
Maddox rod and occluder...
Medicine Products: